What is Retatrutide?
A synthetic triple agonist peptide that simultaneously engages the GLP-1, GIP, and glucagon receptors — currently the most advanced multi-receptor compound in metabolic clinical trials.
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that functions as a triple receptor agonist. It simultaneously activates three distinct receptor systems: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. No prior compound has engaged all three incretin-related pathways in a single molecule.
The peptide is based on a modified GIP backbone with amino acid substitutions that confer agonist activity at all three receptors. This design reflects a growing understanding that metabolic regulation involves multiple overlapping signalling pathways, and that engaging several simultaneously may produce effects that exceed the sum of individual receptor activation.
Retatrutide is currently in Phase 3 clinical trials and is not approved for therapeutic use in any jurisdiction. It is available for research purposes only.
Mechanism
Why Three Receptors?
The rationale for triple agonism builds on the evolution from single-target to multi-target compounds in incretin research. Each receptor contributes a distinct biological signal:
GLP-1 Receptor
Insulin & Satiety
Potentiates glucose-dependent insulin secretion and mediates central appetite signalling. Slows gastric motility. The primary target of first-generation incretin agonists.
GIP Receptor
Insulinotropic & Lipid
Complements GLP-1's insulinotropic effects. Also implicated in lipid metabolism and adipose tissue signalling. Engaged by tirzepatide alongside GLP-1.
Glucagon Receptor
Energy Expenditure
Increases hepatic glucose output and energy expenditure. Counterbalances the insulinotropic effects of GLP-1 and GIP. Adds a catabolic signal to the anabolic incretin effects.
Clinical Trials
The TRIUMPH Programme
Retatrutide's clinical development is organised under the TRIUMPH trial programme — a series of Phase 2 and Phase 3 studies evaluating the compound across multiple metabolic endpoints. Key findings include:
Phase 2
Phase 2 Obesity Study
A 48-week dose-ranging study in adults with obesity demonstrated significant dose-dependent reductions in body weight, with the highest dose producing mean reductions substantially exceeding those observed with single-target GLP-1 agonists in comparable populations.
TRIUMPH-1
First Phase 3 Trial
Evaluating retatrutide in adults with obesity or overweight. Results presented in 2025 confirmed the Phase 2 findings at scale.
TRIUMPH-2
Type 2 Diabetes
Focused on type 2 diabetes with obesity or overweight.
TRIUMPH-Outcomes
Cardiovascular & Kidney
A large-scale cardiovascular and kidney outcomes trial. Currently active but not recruiting. Estimated completion 2029.
SYNERGY-Outcomes
MASLD Investigation
A master protocol evaluating multiple agents for metabolic dysfunction-associated steatotic liver disease (MASLD), with retatrutide among the compounds under investigation.
Australian Research
Australian Participation in Retatrutide Trials
Australian research institutions are deeply involved in the global retatrutide clinical trial programme. ClinicalTrials.gov records show 16 or more Australian sites participating across at least six distinct retatrutide studies, spanning every major state and territory:
NSW
New South Wales
University of Sydney — Charles Perkins Centre, Emeritus Research (Botany), Northern Beaches Clinical Research, The AIM Centre / Hunter Diabetes Centre, Camden Hospital, Woolcock Institute of Medical Research
VIC
Victoria
Box Hill Hospital, Emeritus Research (Camberwell), Austin Health — Repatriation Hospital, Barwon Health (Geelong), The Alfred Hospital, The Royal Melbourne Hospital
QLD
Queensland
Royal Brisbane and Women's Hospital, Core Research Group, Logan Hospital, CDH Research Institute (Maroochydore), Gold Coast University Hospital, Ipswich Hospital
SA
South Australia
Nightingale Research (Adelaide), Flinders University / Flinders Medical Centre, Southern Adelaide Diabetes & Endocrine Services, Fusion Clinical Research
WA
Western Australia
Fiona Stanley Hospital (Murdoch), One Clinical Research (Nedlands), Advara HeartCare Joondalup, TrialsWest (Osborne Park)
ACT
Australian Capital Territory
Canberra Hospital, Paratus Clinical Research Canberra
Research Context
Where Retatrutide Sits
Retatrutide represents the current frontier of incretin-based research — the furthest point along the trajectory from single-target GLP-1 agonists to multi-receptor compounds. Its triple-agonist mechanism is unique among compounds in late-stage clinical development.
The compound's significance extends beyond its individual profile. It serves as a proof of concept for the multi-agonist strategy — demonstrating that engaging three receptor systems simultaneously is both pharmacologically feasible and clinically meaningful. The data emerging from the TRIUMPH programme is shaping how researchers think about metabolic signalling pathways and their interrelationships.
All products are research compounds intended for laboratory research use only. Not for human or veterinary use. Kinetic Labs does not provide dosing guidance, therapeutic recommendations, or medical advice of any kind.